Generic and Biosimilar Cancer Medicines

A Tender Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("THE AUTHORITY")

Source: Find a Tender
Type: Framework (Goods)
Duration: 23.5 month
Value: £59M-£59M

Sector: HEALTH
Published: 16 Sep 2022
Delivery: To 06 Oct 2024 (est.)
Deadline: 17 Oct 2022 11:00

Concepts

Location

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

Geochart for 1 buyers and 0 suppliers

1 buyer

NHS National Services Scotland Edinburgh

Description

This Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland. The Goods have been separated into forty-one (41) categories, each of which is identified as a “Lot”. Full details of each Lot is contained in section II.2 of this Notice.

Lot Division

1	Bendamustine Powder For Solution For Infusion Value: £95K Supply of Bendamustine Powder For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
2	Capecitabine Tablets Value: £911K Supply of Capecitabine Tablets to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
3	Carboplatin Injection Value: £597K Supply of Carboplatin Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
4	Cisplatin Injection Value: £186K Supply of Cisplatin Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
5	Cyclophosphamide Injection, Powder For Reconstitution Value: £267K Supply of Cyclophosphamide Injection, Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
6	Cytarabine Injections Value: £105K Supply of Cytarabine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
7	Dacarbazine Injections Value: £593K Supply of Dacarbazine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
8	Disodium Folinate Injection Value: £442K Supply of Disodium Folinate Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
9	Docetaxel Concentrate For Solution For Infusion Value: £333K Supply of Docetaxel Concentrate For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
10	Doxorubicin Hydrochloride Injections Value: £60K Supply of Doxorubicin Hydrochloride Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
11	Fluorouracil 25MG/ML Injection Value: £45K Supply of Fluorouracil 25MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
12	Fluorouracil 50MG/ML Injection Value: £236K Supply of Fluorouracil 50MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
13	Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials Value: £109K Supply of Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
14	Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials Value: £18K Supply of Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
15	Gemcitabine Powder For Solution For Infusion Vials Value: £126K Supply of Gemcitabine Powder For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
16	Idarubicin Hydrochlioride Injection Powder For Reconstitution Value: £28K Supply of Idarubicin Hydrochlioride Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
17	Ifosfamide Injection Powder For Reconstitution Value: £3M Supply of Ifosfamide Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
18	Irinotecan Hydrochloride Injection Value: £248K Supply of Irinotecan Hydrochloride Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
19	Lanreotide Injection Prefilled Syringes Value: £5M Supply of Lanreotide Injection Prefilled Syringes to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
20	Methotrexate Without Preservatives Injection Value: £305K Supply of Methotrexate Without Preservatives Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
21	Methotrexate Oral Solution Value: £56K Supply of Methotrexate Oral Solution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
22	Mitomycin Injection Powder For Reconstitution Value: £495K Supply of Mitomycin Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
23	Oxaliplatin Vial Solution Value: £209K Supply of Oxaliplatin Vial Solution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
24	Paclitaxel Concentrate For Intravenous Infusion Value: £407K Supply of Paclitaxel Concentrate For Intravenous Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
25	Temozolomide Capsules Value: £146K Supply of Temozolomide Capsules to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
26	Vincristine Without Preservatives Injection Value: £71K Supply of Vincristine Without Preservatives Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
27	Vinorelbine Injection Value: £54K Supply of Vinorelbine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
28	Aprepitant Capsules Value: £116K Supply of Aprepitant Capsules to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.
29	Lot 29 Topotecan Capsules Value: £124K Supply of Topotecan Capsules to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.
30	Topotecan Concentrate For Solution For Infusion Value: £137K Supply of Topotecan Concentrate For Solution For Infusion to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents
31	Octreotide Injection Value: £167K Supply of Octreotide Injection. The Authority intends awarding all presentations within this lot to a single supplier. Full details of Goods and volumes can be found within the ITT documents.
32	Filgrastim Pre-Filled Syringe Value: £2M Supply of Filgrastim Pre-Filled Syringe to NHS Scotland in a range of presentations. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
33	Pemetrexed Powder For Solution For Infusion Vials Value: £198K Supply of Pemetrexed Powder For Solution For Infusion Vials in various presentations to NHS Scotland. The Authority intends to award this Lot as a single-supplier framework. Full details of Goods and volumes can be found within the ITT documents.
34	Pemetrexed (25Mg/Ml) Solution For Infusion Vials Value: £212K Supply of Pemetrexed (25Mg/Ml) Solution For Infusion Vials to NHS Scotland in a range of presentations. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.
35	Octreotide Vials Long Acting (Excluding Homecare) Value: £221K Supply of Octreotide Vials Long Acting (Excluding Homecare) to NHS Scotland. The Authority intends awarding each product line as a multi-supplier unranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded.
36	Octreotide Vials Long Acting (Including Homecare) Value: £2M Supply of Octreotide Vials Long Acting (Including Homecare) to NHS Scotland. The Authority intends awarding each product line as a multi-supplier unranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded. Full details can be found within the ITT.
37	Etoposide Injection Value: £168K Supply of Etoposide Injection to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier framework to a maximum of three (3) Framework Participants. Full details of Goods and volumes can be found within the ITT documents.
38	Dasatinib Tablets Value: £143K Supply of Dasatinib Tablets to NHS Scotland. The Authority intends awarding each product line as a multi-supplier ranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded. Full details of Goods and volumes can be found within the ITT documents.
39	Unranked Multi-Supplier Generic & Biosimilar Medicines Value: £11M Supply of a number of Generic & Biosimilar Medicines including bevacizumab solution for infusion, doxorubicin liposomal solution for infusion, rituximab solution for infusion, trastuzumab powder for solution for infusion, sorafenib tablets and thalidomide capsules to NHS Scotland. Each product line will be treated as an individual Lot and awarded as a unranked multi-supplier to an envisaged maximum of 6 Framework Participants. Full details of Goods and volumes can be found within the ITT documents.
40	Idarubicin Hydrochloride Solution for Infusion Value: £13K Supply of Idarubicin Hydrochloride Solution for Infusion. The Authority intends awarding all presentations within this lot to a single supplier. Full details of Goods and volumes can be found within the ITT documents.
41	Single Supplier Generic Medicines Value: £30M Supply of a range of generic cancer medicines to NHS Scotland. Each product line will be treated as an individual Lot and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.

Award Criteria

Logistics	5
price	95

CPV Codes

33600000 - Pharmaceutical products

Indicators

This is a one-off contract (no recurrence)
Renewals are available.
Technical restrictions apply.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value referred to in Section II.I.5 and within each Lot covers the twenty-four (24) months contract duration and the full twenty-four (24) months extension options. The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 22063. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343 A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363 Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-pr... A summary of the expected community benefits has been provided as follows: It is a mandatory requirement that Potential Framework Participants agree to support the concept, provision and ongoing development of community benefits provision in relation to this framework. Potential Framework Participants are required to agree to this mandatory requirement. They are also requested to provide a brief summary of the community benefits that have recently been delivered within Scotland, if at all, and also what impact and outcomes these have achieved. Potential Framework Participants are required to summarise any proposed community benefits that will be developed and delivered as part of this contract if successful or, alternatively, Potential Framework Participants confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits. For further information please visit www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-b... (SC Ref:705779)

Reference

ocds-h6vhtk-0368ee
FTS 025989-2022